The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson’s disease

Table 4 Qualitative evaluation of the temporal changes in IBA1 and GFAP immunostaining after MPTP treatment

		Time after the last injection of MPTP
		2 h	1 day	2 days	4 days	7 days
Striatum	IBA1	+	+++	+++	+	+
	GFAP	0	+	+++	+++	++
SNpc	IBA1	0	++	+++	+++	++
	GFAP	0	+	+++	+++	++

Changes in IBA1 and GFAP immunolabelling vs. control mice: 0 = similar to control; + = some cells, ++ = moderate number of cells and +++ = many cells with hypertrophied morphology and intensified IBA1 or GFAP staining

ISSN: 1742-2094